India took a much-needed step in the fight against obesity and diabetes with the introduction of Mounjaro (tirzepatide), a ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

The new weight loss drug entering the Indian market, Mounjaro, Trinamool Congress' MP Abhishek Banerjee's Diamond Harbour Model and his political ascent in West Bengal and the Waqf Amendment Bill, ...

US -based pharmaceutical giant Eli Lilly recently launched its weight loss drug Mounjaro in India. Tirzepatide is the generic ...

A patient in India may have to spend approximately $200 per month for ... Following marketing authorization from the CDSCO, ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...